RARA CRAFT DATABASE for FDA Medical Devices
510(k)K260619

FDA DEVICE FACTS

VITEK 2 AST-Streptococcus Cefepime (<=0.06 – >=4 µg/mL)

Biomérieux, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

PCCP: Authorized
DECISION DATESeptember 28, 2026PRODUCT CODELON

Indications for use

VITEK 2 AST-Streptococcus Cefepime (≤0.06 - ≥4 µg/mL) is designed for antimicrobial susceptibility testing of Streptococcus species and is intended for use with the VITEK 2 Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 AST-Streptococcus Cefepime (≤0.06 - ≥4 µg/mL) is a quantitative test. Testing is indicated for Streptococcus pneumoniae (non-meningitis), Streptococcus spp. β-Hemolytic Group and Streptococcus spp. Viridans Group, as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). VITEK 2 AST-Streptococcus Cefepime (≤0.06 - ≥4 µg/mL) has demonstrated acceptable performance with the following organisms: Streptococcus pneumoniae (non-meningitis) Streptococcus spp. β-Hemolytic Group (Streptococcus agalactiae, Streptococcus canis, Streptococcus dysgalactiae ssp. equisimilis, Streptococcus equisimilis ssp. zooepidemicus, Streptococcus pyogenes) Streptococcus spp. Viridans Group (Streptococcus cristatus, Streptococcus gallolyticus ssp. gallolyticus, Streptococcus gordonii, Streptococcus infantarius ssp. infantarius, Streptococcus mitis, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus salivarius ssp. salivarius, Streptococcus sanguinis, Streptococcus uberis, Streptococcus vestibularis) The VITEK 2 Streptococcus Susceptibility Card is intended for use with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of Streptococcus pneumoniae, beta-hemolytic Streptococcus, and Viridans Streptococcus to antimicrobial agents when used as instructed.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: October 7, 2026